Recent updates on ocular disease management with ophthalmic ointments

References

• Krishnaswami V, Kandasamy R, Alagarsamy S, et al. Biological macromolecules for ophthalmic drug delivery to treat ocular diseases. Int J Biol Macromol. 2018;110:7–16. doi:10.1016/j.ijbiomac.2018.01.120
   PubMed Web of Science ®Google Scholar
• Chitra PS, Chaki D, Boiroju NK, et al. Status of oxidative stress markers, advanced glycation index, and polyol pathway in age-related cataract subjects with and without diabetes. Exp Eye Res. 2020;200:108230. doi:10.1016/j.exer.2020.108230
   PubMed Web of Science ®Google Scholar
• Weinberg J, Gaur M, Swaroop A, et al. Proteostasis in aging-associated ocular disease. Mol Aspects Med. 2022;88:101157. doi:10.1016/j.mam.2022.101157
   PubMed Web of Science ®Google Scholar
• Sayin N, Kara N, Pekel G. Ocular complications of diabetes mellitus. World J Diabetes. 2015;6:92–108. doi:10.4239/wjd.v6.i1.92
   PubMed Web of Science ®Google Scholar
• Ramírez-Soto MC, Bonifaz A. Ocular fungal infections. J Fungi. 2022;8:1078. doi:10.3390/jof8101078
   Web of Science ®Google Scholar
• Mitchell P, Liew G, Gopinath B, et al. Age-related macular degeneration. Lancet 2018;392:1147–1159. doi:10.1016/S0140-6736(18)31550-2
   PubMed Web of Science ®Google Scholar
• Biswas A, Choudhury AD, Agrawal S, et al. Recent insights into the etiopathogenesis of diabetic retinopathy and its management. J Ocul Pharmacol Ther. 2024;40:13–33. doi:10.1089/jop.2023.0068
   PubMed Web of Science ®Google Scholar
• Dimaras H, Corson TW, Cobrinik D, et al. Retinoblastoma. Nat Rev Dis Prim. 2015;1:1–23. doi:10.1038/nrdp.2015.21
   Web of Science ®Google Scholar
• Lam D, Rao SK, Ratra V, et al. Cataract. Nat Rev Dis Prim. 2015;1:1–15.
   Web of Science ®Google Scholar
• Khan MA, Brady CJ, Kaiser RS. Clinical management of proliferative vitreoretinopathy: an update. Retina. 2015;35:165–175. doi:10.1097/IAE.0000000000000447
   PubMed Web of Science ®Google Scholar
• Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26:2–16. doi:10.1080/09273948.2016.1196713
   PubMed Web of Science ®Google Scholar
• Dioverti MV, Razonable RR. Cytomegalovirus. In: Hayden RT, Wolk DM, Carroll KC, Tang Y, editors. Diagnostic Microbiol Immunocompromised Host. 2016;97–125. doi:10.1128/9781555819040.ch4
   Google Scholar
• Leske MC. Open-angle glaucoma – An epidemiologic overview. Ophthalmic Epidemiol. 2007;14:166–172. doi:10.1080/09286580701501931
   PubMed Web of Science ®Google Scholar
• Wadhwa S, Paliwal R, Paliwal SR, et al. Nanocarriers in ocular drug delivery: an update review. Curr Pharm Des. 2009;15:2724–2750. doi:10.2174/138161209788923886
   PubMed Web of Science ®Google Scholar
• Ahmed S, Amin MM, Sayed S. Ocular drug delivery: a comprehensive review. AAPS PharmSciTech. 2023;24:66. doi:10.1208/s12249-023-02516-9
   PubMed Web of Science ®Google Scholar
• Dubald M, Bourgeois S, Andrieu V, et al. Ophthalmic drug delivery systems for antibiotherapy – A review. Pharmaceutics. 2018;10:10. doi:10.3390/pharmaceutics10010010
   PubMed Web of Science ®Google Scholar
• Gan L, Wang J, Jiang M, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today. 2013;18:290–297. doi:10.1016/j.drudis.2012.10.005
   PubMed Web of Science ®Google Scholar
• Morrison PWJ, Khutoryanskiy VV. Advances in ophthalmic drug delivery. Ther Deliv. 2014;5:1297–1315. doi:10.4155/tde.14.75
   PubMedGoogle Scholar
• Maulvi FA, Shetty KH, Desai DT, et al. Recent advances in ophthalmic preparations: ocular barriers, dosage forms and routes of administration. Int J Pharm. 2021;608:121105. doi:10.1016/j.ijpharm.2021.121105
   PubMed Web of Science ®Google Scholar
• Ahmed S, Amin MM, El-Korany SM, et al. Corneal targeted fenticonazole nitrate-loaded novasomes for the management of ocular candidiasis: preparation, in vitro characterization, ex vivo and in vivo assessments. Drug Deliv. 2022;29:2428–2441. doi:10.1080/10717544.2022.2103600
   PubMed Web of Science ®Google Scholar
• Ahmed S, Amin MM, Sayed S. Ocular drug delivery: a comprehensive review. AAPS PharmSciTech. 2023;24(2):66. doi:10.1208/s12249-023-02516-9
   PubMed Web of Science ®Google Scholar
• Bisen AC, Srivastava S, Mishra A, et al. Pharmaceutical Emulsions: A Viable Approach for Ocular Drug Delivery. J Ocul Pharmacol Ther. 2024. [ accessed 2024 April 29]. doi:10.1089/jop.2023.0166
   Web of Science ®Google Scholar
• Sanap SN, Bisen AC, Kedar A, et al. Chitosan/HPMC-based mucoadhesive film co-loaded with fluconazole and ofloxacin for management of polymicrobial keratitis. Int J Biol Macromol. 2022;222:2785–2795. doi:10.1016/j.ijbiomac.2022.10.058
   PubMed Web of Science ®Google Scholar
• Le Bourlais C, Acar L, Zia H, et al. Ophthalmic drug delivery systems – Recent advances. Prog Retin Eye Res. 1998;17:33–58. doi:10.1016/S1350-9462(97)00002-5
   PubMed Web of Science ®Google Scholar
• Bao Q, Jog R, Shen J, et al. Physicochemical attributes and dissolution testing of ophthalmic ointments. Int J Pharm. 2017;523:310–319. doi:10.1016/j.ijpharm.2017.03.039
   PubMedGoogle Scholar
• Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002;28:473–493. doi:10.1081/DDC-120003445
   PubMed Web of Science ®Google Scholar
• Araújo J, Gonzalez E, Egea MA, et al. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomed Nanotechnol Biol Med. 2009;5:394–401. doi:10.1016/j.nano.2009.02.003
   PubMed Web of Science ®Google Scholar
• Gaudana R, Ananthula HK, Parenky A, et al. Ocular drug delivery. AAPS J. 2010;12:348–360. doi:10.1208/s12248-010-9183-3
   PubMed Web of Science ®Google Scholar
• Kompella UB, Kadam RS, Lee. Kompella, Kadam, Lee – 2010 – Recent advances in ophthalmic drug delivery. Ther Deliv. 2010;1:435–456. doi:10.4155/tde.10.40
   PubMedGoogle Scholar
• Yadav KS, Bisen AC, Ishteyaque S, et al. Solanum nigrum toxicity and its neuroprotective effect against retinal ganglion cell death through modulation of extracellular matrix in a glaucoma rat model. J Ocul Pharmacol Ther. 2024. doi:10.1089/jop.2023.0089 ( Epub ahead of print).
   Web of Science ®Google Scholar
• Geroski D, Edelhauser H. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000;41:961–964.
   PubMed Web of Science ®Google Scholar
• Bastawrous A, Burgess PI, Mahdi AM, et al. Posterior segment eye disease in sub-Saharan Africa: review of recent population-based studies. Trop Med Int Health. 2014;19:600–609. doi:10.1111/tmi.12276
   PubMed Web of Science ®Google Scholar
• Amo EM, Urtti A. Current and future ophthalmic drug delivery systems A shift to the posterior segment. Drug Discov Today. 2008;13:135–143.
   PubMed Web of Science ®Google Scholar
• Naqvi SSS, Waqas A, Mehmood Y, et al. Eye and eyelid infection among females using kajal and mascara. J Contemp Pharm. 2017;1:8–12. doi:10.56770/jcp201702
   Google Scholar
• Singh P, Bhalerao S, Rani PK. Self-medication complicating pseudo membranous conjunctivitis. BMJ Case Rep. 2017;2017:1–3. doi:10.1136/bcr-2017-219907
   Google Scholar
• Jeffrey S, Robin PPE. Ophthalmic ointments. Surv Ophthalmol. 1978;22:335–340.
   Web of Science ®Google Scholar
• Sasaki H, Yamamura K, Mukai T, et al. Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst. 1999;16:85–146. doi:10.1615/CritRevTherDrugCarrierSyst.v16.i1.20
   PubMed Web of Science ®Google Scholar
• Castro-Balado A, Mondelo-García C, Zarra-Ferro I, et al. New ophthalmic drug delivery systems. Farm Hosp. 2020;44:149–157.
   PubMed Web of Science ®Google Scholar
• Rathore KS, Nema RK. An insight into ophthalmic drug delivery system. Int J Pharm Sci Drug Res. 2009;1:1–5.
   Google Scholar
• Al-Ghabeish M, Xu X, Krishnaiah YSR, et al. Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment. Int J Pharm. 2015;495:783–791. doi:10.1016/j.ijpharm.2015.08.096
   PubMedGoogle Scholar
• Hardberger RE, Hanna C, Boyd CM. Effects of drug vehicles on ocular contact time. Am J Ophthalmol. 1975;80:133–138. doi:10.1016/0002-9394(75)90883-1
   PubMed Web of Science ®Google Scholar
• Watson S, Cabrera-Aguas M, Khoo P. Common eye infections. Aust Prescr. 2018;41:67. doi:10.18773/austprescr.2018.016
   PubMedGoogle Scholar
• Bisen AC, Agrawal S, Rayiti R, et al. Pirfenidone: a promising drug in ocular therapeutics. Chem Biodivers. 2024;21:e202301389. doi:10.1002/cbdv.202301389
   PubMed Web of Science ®Google Scholar
• Bokil P, Sanap G, Shubhangi Manikpuriya SMM. Employment opportunities in solar energy sector. Int J Adv Res Sci Commun Technol. 2022;6:323–335.
   Google Scholar
• Shaw C. Chapter 7 – Preparation and Stability Testing. In: Kulkarni VS, editor. Shaw CBT-EC for F of S and LD. Boston: Academic Press; 2016. p. 99–135.
   Google Scholar
• Greaves JL, Wilson CG, Birmingham AT. Assessment of the precorneal residence of an ophthalmic ointment in healthy subjects. Br J Clin Pharmacol. 1993;35:188.
   PubMed Web of Science ®Google Scholar
• Ghosh M, Ahmed I. Chemistry, manufacturing, and control of ophthalmic formulations. Methods Pharmacol Toxicol. 2013;53–79. doi:10.1007/7653_2013_9
   Google Scholar
• Yilmaz OF, Sarmis A, Mutlu MA, et al. Bacterial contamination of multi-use tear drops, gels, and ointments. Contact Lens Anterior Eye. 2023;46:102064. doi:10.1016/j.clae.2023.102064
   PubMed Web of Science ®Google Scholar
• Yilmaz OF, Sarmis A, Mutlu MA, et al. Bacterial contamination of multi-use antibiotic steroid eye ointments and drops. Graefe's Arch Clin Exp Ophthalmol. 2023;261:1691–1700. doi:10.1007/s00417-023-05977-7
   PubMed Web of Science ®Google Scholar
• Sarkar R. Effects of preservatives used in ocular medications on the eye: a comparative review. Ophthalmol J. 2021;6:44–52. doi:10.5603/OJ.2021.0009
   Google Scholar
• Coroi MC, Bungau S, Tit M. Preservatives from the eye drops and the ocular surface. Rom J Ophthalmol. 2015;59:2.
   PubMedGoogle Scholar
• Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol. 2009;4:59–64. doi:10.1586/17469899.4.1.59
   Google Scholar
• Gautam S, Marwaha D, Singh N, et al. Self-assembled redox-sensitive polymeric nanostructures facilitate the intracellular delivery of paclitaxel for improved breast cancer therapy. Mol Pharm. 2023;20:1914–1932. doi:10.1021/acs.molpharmaceut.2c00673
   PubMedGoogle Scholar
• Marwaha D, Gautam S, Singh N, et al. Synergistic delivery of Imatinib through multifunctional nano-crystalline capsules, in response to redox environment for improved breast cancer therapy. Colloid. Surf. B Biointerf. 2023;226:113316. doi:10.1016/j.colsurfb.2023.113316
   PubMed Web of Science ®Google Scholar
• Singh N, Marwaha D, Gautam S, et al. Surface-modified lyotropic crystalline nanoconstructs bearing doxorubicin and buparvaquone target sigma receptors through pH-sensitive charge conversion to improve breast cancer therapy. Biomacromolecules. 2023;24:5780–5796. doi:10.1021/acs.biomac.3c00795
   PubMed Web of Science ®Google Scholar
• De Villiers MM, Marques M, Mille Y, et al. Ointment Bases. In: Thompson JE, editor. A Pract Guid to Contemp Pharm Pract. 3rd ed. Judith E Thompson; 2009.
   Google Scholar
• Bao Q, Shen J, Jog R, et al. In vitro release testing method development for ophthalmic ointments. Int J Pharm. 2017;526:145–156. doi:10.1016/j.ijpharm.2017.04.075
   PubMedGoogle Scholar
• Bhaskar R, Ola M, Patil PH, et al. A review on: ointment and ointment bases. World J Pharm Res. 2016;5:335–345.
   Google Scholar
• Keen M, L D. Aqueous formulations and ointments. Int Ophthalmol Clin. 1980;20:79–92. doi:10.1097/00004397-198002030-00009
   PubMedGoogle Scholar
• Ahuja M, Dhake AS, Sharma SK, et al. Topical ocular delivery of NSAIDs. AAPS J. 2008;10:229–241. doi:10.1208/s12248-008-9024-9
   PubMed Web of Science ®Google Scholar
• Grant DM. Acyclovir (ZoviraxR) ophthalmic ointment: a review of clinical tolerance. Curr Eye Res. 1987;6:231–235. doi:10.3109/02713688709020096
   PubMed Web of Science ®Google Scholar
• Patel A. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2:47. doi:10.5497/wjp.v2.i2.47
   PubMedGoogle Scholar
• Tiwari P, Shukla RP, Yadav K, et al. Dacarbazine-primed carbon quantum dots coated with breast cancer cell-derived exosomes for improved breast cancer therapy. J Control Rel. 2024;365:43–59. doi:10.1016/j.jconrel.2023.11.005
   PubMed Web of Science ®Google Scholar
• Tiwari P, Yadav K, Shukla RP, et al. Surface modification strategies in translocating nano-vesicles across different barriers and the role of bio-vesicles in improving anticancer therapy. J Control Rel. 2023;363:290–348. doi:10.1016/j.jconrel.2023.09.016
   PubMed Web of Science ®Google Scholar
• Tiwari P, Shukla RP, Yadav K, et al. Exploring nanocarriers as innovative materials for advanced drug delivery strategies in onco-immunotherapies. J Mol Graph Model. 2024;128:108702. doi:10.1016/j.jmgm.2024.108702
   PubMed Web of Science ®Google Scholar
• Shukla RP, Urandur S, Banala VT, et al. Development of putrescine anchored nano-crystalsomes bearing doxorubicin and oleanolic acid: deciphering their role in inhibiting metastatic breast cancer. Biomater Sci. 2021;9:1779–1794. doi:10.1039/D0BM01033B
   PubMed Web of Science ®Google Scholar
• Cabrera FJ, Wang DC, Reddy K, Acharya G, Shin CS. Challenges and opportunities for drug delivery to the posterior of the eye. Drug Discov Today. 2019;24:1679–1684. doi:10.1016/j.drudis.2019.05.035
   PubMed Web of Science ®Google Scholar
• Nayak K, Misra M. A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother. 2018;107:1564–1582. doi:10.1016/j.biopha.2018.08.138
   PubMed Web of Science ®Google Scholar
• Agrahari V, Agrahari V, Mandal A, et al. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches. Expert Opin Drug Deliv. 2017;14:1145–1162. doi:10.1080/17425247.2017.1272569
   PubMed Web of Science ®Google Scholar
• Biswas A, Choudhury AD, Bisen AC, et al. Trends in formulation approaches for sustained drug delivery to the posterior segment of the eye. AAPS PharmSciTech. 2023;24:217. doi:10.1208/s12249-023-02673-x
   PubMed Web of Science ®Google Scholar
• Sanap SN, Bisen AC, Agrawal S, et al. Ophthalmic nano-bioconjugates: critical challenges and technological advances. Ther Deliv. 2023;14:419–441. doi:10.4155/tde-2023-0031
   PubMed Web of Science ®Google Scholar
• Dartt D, Willcox M. Complexity of the tear film: importance in homeostasis and dysfunction during disease. Exp Eye Res. 2013;117:1–3. doi:10.1016/j.exer.2013.10.008
   PubMed Web of Science ®Google Scholar
• Millar TJ, Schuett BS. The real reason for having a meibomian lipid layer covering the outer surface of the tear film – A review. Exp Eye Res. 2015;137:125–138. doi:10.1016/j.exer.2015.05.002
   PubMed Web of Science ®Google Scholar
• Wang J, Fonn D, Simpson TL, et al. Precorneal and pre- and postlens tear film thickness measured indirectly with optical coherence tomography. Investig Ophthalmol Vis Sci. 2003;44:2524–2528. doi:10.1167/iovs.02-0731
   PubMed Web of Science ®Google Scholar
• Ragland SA, Criss AK. From bacterial killing to immune modulation: recent insights into the functions of lysozyme. PLoS Pathog. 2017;13:1–22. doi:10.1371/journal.ppat.1006512
   Web of Science ®Google Scholar
• Prausnitz MR, Noonan JS. Permeability of cornea, sciera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87:1479–1488. doi:10.1021/js9802594
   PubMed Web of Science ®Google Scholar
• DelMonte DW, Kim T. Anatomy and physiology of the cornea. J Cataract Refract Surg. 2011;37:588–598. doi:10.1016/j.jcrs.2010.12.037
   PubMed Web of Science ®Google Scholar
• Moiseev RV, Morrison PWJ, Steele F, et al. Penetration enhancers in ocular drug delivery. Pharmaceutics. 2019;11:321. doi:10.3390/pharmaceutics11070321
   PubMed Web of Science ®Google Scholar
• Agrahari V, Mandal A, Agrahari V, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6:735–754. doi:10.1007/s13346-016-0339-2
   PubMed Web of Science ®Google Scholar
• Akram A, Debnath R. An automated eye disease recognition system from visual content of facial images using machine learning techniques. Turkish J Electr Eng Comput Sci. 2020;28:917–932. doi:10.3906/elk-1905-42
   Web of Science ®Google Scholar
• Sanap SN, Bisen AC, Mishra A, et al. QbD based antifungal drug-loaded ophthalmic liposomal formulation for the management of fungal keratitis: in vitro, ex vivo and in vivo pharmacokinetic studies. J Drug Deliv Sci Technol. 2022;74:103517.
   Web of Science ®Google Scholar
• Bisen AC, Bhatta RS. Ocular bioanalysis of moxifloxacin and ketorolac tromethamine in rabbit lacrimal matrix using liquid chromatography-tandem mass spectrometry. Bioanalysis. 2024;16:219–232. doi:10.4155/bio-2023-0233
   PubMed Web of Science ®Google Scholar
• Bisen AC, Agrawal S, Sanap SN, et al. Simultaneous estimation of voriconazole, moxifloxacin, and pirfenidone in rabbit lacrimal matrix using LC-MS/MS: an application to preclinical ocular pharmacokinetics. Anal Methods. 2023;15:2234–2243. doi:10.1039/D3AY00317E
   PubMed Web of Science ®Google Scholar
• Bisen AC, Sanap SN, Biswas A, et al. A QbD-led simple and sensitive RP-UHPLC method for simultaneous determination of moxifloxacin, voriconazole, and pirfenidone: an application to pharmaceutical analysis. Biomed Chromatogr. 2023;37:e5681. doi:10.1002/bmc.5681
   PubMed Web of Science ®Google Scholar
• Agrawal S, Bisen AC, Biswas A, et al. Simultaneous pharmacokinetic assessment of phytopharmaceuticals in fenugreek extract using LC-MS/MS in Sprague-Dawley rats. Biomed Chromatogr. 2023;37:e5600. doi:10.1002/bmc.5600
   PubMed Web of Science ®Google Scholar
• Goldschmidt P, Degorge S, Sarria PC, et al. New strategy for rapid diagnosis and characterization of fungal infections: the example of corneal scrapings. PLOS ONE. 2012;7:16–17. doi:10.1371/journal.pone.0037660
   Web of Science ®Google Scholar
• Sanap SN, Kedar A, Bisen AC, et al. A recent update on therapeutic potential of vesicular system against fungal keratitis. J Drug Deliv Sci Technol. 2022;75:103721. doi:10.1016/j.jddst.2022.103721
   Web of Science ®Google Scholar
• Ibrahim MM, de Angelis R, Lima AS, et al. A new method to predict the epidemiology of fungal keratitis by monitoring the sales distribution of antifungal eye drops in Brazil. PLOS ONE. 2012;7:e33775. doi:10.1371/journal.pone.0033775
   PubMed Web of Science ®Google Scholar
• Bisen AC, Mishra A, Agrawal S, et al. Codetermination of antimicrobial agents in rabbit tear fluid using LC–MS/MS assay: Insights into ocular pharmacokinetic study. J Mass Spectrom. 2024;59(6):e5031. doi:10.1002/jms.5031
   PubMed Web of Science ®Google Scholar
• Mishra A, Bano M, Bisen AC, et al. Topical corneal targeted sustained release amphotericin B liposomal formulation for the treatment of fungal keratitis and its PK-PD evaluation. J Drug Deliv Sci Technol. 2020;60:101944. doi:10.1016/j.jddst.2020.101944
   Web of Science ®Google Scholar
• Sanap SN, Bisen AC, Kedar A, et al. Recent update on pharmacokinetics and drug metabolism in CNS-based drug discovery. Curr Pharm Des. 2023;29:1602–1616. doi:10.2174/1381612829666230707121415
   PubMed Web of Science ®Google Scholar
• Eguchi H, Shiota H, Oguro S, et al. The inhibitory effect of vancomycin ointment on the manifestation of MRSA keratitis in rabbits. J Infect Chemother. 2009;15:279–283.
   PubMed Web of Science ®Google Scholar
• Fatohy H. Formulation of econazole nitrate as an ophthalmic ointment. Zanco J Med Sci. 2009;13:73–78. doi:10.15218/zjms.2009.023
   Google Scholar
• Fukuda M, Hanazome I, Sasaki K. The intraocular dynamics of vancomycin hydrochloride ophthalmic ointment (TN-011) in rabbits. J Infect Chemother. 2003;9:93–96. doi:10.1007/s10156-002-0219-1
   PubMedGoogle Scholar
• Sotozono C, Fukuda M, Ohishi M, et al. Vancomycin ophthalmic ointment 1% for methicillin-resistant Staphylococcus aureus or methicillin-resistant Staphylococcus epidermidis infections: a case series. BMJ Open. 2013;3:3–7.
   Web of Science ®Google Scholar
• Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al. 0.3% Ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. Arch Ophthalmol. 1993;111:1210–1218. doi:10.1001/archopht.1993.01090090062020
   PubMedGoogle Scholar
• Randazzo J, Zhang P, Makita J, et al. Orally active multi-functional antioxidants delay cataract formation in streptozotocin (Type 1) diabetic and gamma-irradiated rats. PLOS ONE. 2011;6:e18980. doi:10.1371/journal.pone.0018980
   PubMed Web of Science ®Google Scholar
• Ho M, Peng Y, Chen S, et al. Senile cataracts and oxidative stress. J Clin Gerontol Geriatr. 2010;1:17–21. doi:10.1016/j.jcgg.2010.10.006
   Google Scholar
• Bell TAG, Slack M, Harvey SG, et al. The effect of trimethoprim-polymyxin B sulphate ophthalmic ointment and chloramphenicol ophthalmic ointment on the bacterial flora of the eye when administered to the operated and unoperated eyes of patients undergoing cataract surgery. Eye 1988;2:324–329. doi:10.1038/eye.1988.61
   PubMed Web of Science ®Google Scholar
• Mazet R, Yaméogo JBG, Wouessidjewe D, et al. Recent advances in the design of topical ophthalmic delivery systems in the treatment of ocular surface inflammation and their biopharmaceutical evaluation. Pharmaceutics. 2020;12:1–56. doi:10.3390/pharmaceutics12060570
   Web of Science ®Google Scholar
• Elzomor H, Taha H, Aleieldin A, et al. High risk retinoblastoma: prevalence and success of treatment in developing countries. Ophthalmic Genet. 2015;36:287–289. doi:10.3109/13816810.2015.1016241
   PubMed Web of Science ®Google Scholar
• Corson TW, Samuels BC, Wenzel AA, et al. Multimodality imaging methods for assessing retinoblastoma orthotopic xenograft growth and development. PLOS ONE. 2014;9:e99036. doi:10.1371/journal.pone.0099036
   PubMed Web of Science ®Google Scholar
• Thomas CD, Lupu M, Poyer F, et al. Increased PDT efficacy when associated with nitroglycerin: a study on retinoblastoma xenografted on mice. Pharmaceuticals. 2022;15:1–12. doi:10.3390/ph15080985
   Web of Science ®Google Scholar
• Hosoya K, Lee VHL, Kim K. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur J Pharm Biopharm. 2005;60:227–240. doi:10.1016/j.ejpb.2004.12.007
   PubMed Web of Science ®Google Scholar
• Saha BC, Kumari R, Ambasta A. Comparision of efficacy and safety of 0.03% and 0.1% tacrolimus ointment in children with vernal keratoconjunctivitis. Ther Adv Ophthalmol. 2023;15:25158414231173532. doi:10.1177/25158414231173532
   Web of Science ®Google Scholar
• Randive DS, Bhinge SD, Bhutkar MA, et al. Single walled carbon nanotube: chitosan conjugate for sustained ophthalmic delivery of Ciprofloxacin from ointment; its evaluation and in vivo eye irritation study. Sep Sci Technol. 2023;58:775–788. doi:10.1080/01496395.2022.2160349
   Web of Science ®Google Scholar
• Perez Garcia D, Juan Ibanez A, Orobia AJM, et al. Topical tacrolimus ointment for treatment of intractable atopic keratoconjunctivitis: a case report and review of the literature. Cornea 2011;30:462–465. doi:10.1097/ICO.0b013e3181d83875
   PubMed Web of Science ®Google Scholar
• Liu FY, Liu HY, Chu HS, et al. Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis. Graefe's Arch Clin Exp Ophthalmol. 2019;257(5):967–974. doi:10.1007/s00417-019-04287-1
   PubMed Web of Science ®Google Scholar
• Ryu EH, Kim JM, Laddha PM. Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis. Korean Ophthalmol Soc. 2012;26:241–247. doi:10.3341/kjo.2012.26.4.241
   Google Scholar
• Malhotra M, Majumdar DK. Aqueous, oil, and ointment formulations of ketorolac: efficacy against prostaglandin E2-induced ocular inflammation and safety: a technical note. AAPS PharmSciTech. 2006;7:E1–E6. doi:10.1208/pt070496
   PubMed Web of Science ®Google Scholar
• Algarni AM, Guyatt GH, Turner A, et al. Antibiotic prophylaxis for corneal abrasion. Cochrane Database Syst Rev. 2022;5:CD014617.
   PubMedGoogle Scholar
• Quigley H, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267. doi:10.1136/bjo.2005.081224
   PubMed Web of Science ®Google Scholar
• Serle JB. Pharmacological advances in the treatment of glaucoma. Drug Ther (NY). 1994;5:156–170. doi:10.2165/00002512-199405030-00002
   Google Scholar
• Sakassegawa-naves FE, Maria H, Ricci M, et al. Tacrolimus ointment for refractory posterior blepharitis tacrolimus ointment for refractory posterior blepharitis. Curr Eye Res. 2017;42:1440–1444. doi:10.1080/02713683.2017.1339805
   PubMed Web of Science ®Google Scholar
• Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Investig Ophthalmol Vis Sci. 2005;46:3089–3094. doi:10.1167/iovs.05-0275
   PubMed Web of Science ®Google Scholar
• Aumond S, Bitton E. Palpebral and facial skin infestation by Demodex folliculorum. Contact Lens Anterior Eye. 2020;43:115–122. doi:10.1016/j.clae.2019.09.001
   PubMed Web of Science ®Google Scholar
• Gao YY, Xu DL, Huang LJ, et al. Treatment of ocular itching associated with ocular demodicosis by 5% tea tree oil ointment. Cornea. 2012;31:14–17. doi:10.1097/ICO.0b013e31820ce56c
   PubMed Web of Science ®Google Scholar
• Duplechain A, Conrady CD, Patel BC, et al. Uveitis. StatPearls. Treasure Island (FL); 2023.
   Google Scholar
• Bisen AC, Agrawal S, Sanap SN, et al. COVID-19 retreats and world recovers: a silver lining in the dark cloud. Heal Care Sci. 2023;2:264–285. doi:10.1002/hcs2.57
   Google Scholar
• Delwig A, Keenan JD, Margolis TP. Topical valganciclovir for the treatment of hypertensive anterior uveitis. Cornea. 2015;34:1513–1515. doi:10.1097/ICO.0000000000000579
   PubMed Web of Science ®Google Scholar
• Kuo YK, Lin IC, Chien LN, et al. Dry eye disease: a review of epidemiology in Taiwan, and its clinical treatment and merits. J Clin Med. 2019;8:1227. doi:10.3390/jcm8081227
   PubMed Web of Science ®Google Scholar
• Biswas A, Kumar S, Choudhury AD, et al. Polymers and their engineered analogues for ocular drug delivery: enhancing therapeutic precision. Biopolymers. 2024;n/a:e23578. doi:10.1002/bip.23578
   Google Scholar
• Bisen AC, Biswas A, Dubey A, et al. A review on polymers in ocular drug delivery systems. MedComm – Biomater Appl. 2024;3:e77. doi:10.1002/mba2.77
   Google Scholar
• Zhang W, Wang Y, Lee BTK, et al. A novel nanoscale-dispersed eye ointment for the treatment of dry eye disease. Nanotechnology. 2014;25:125101. doi:10.1088/0957-4484/25/12/125101
   PubMed Web of Science ®Google Scholar
• Tsubota K, Monden Y, Yagi Y, et al. New treatment of dry eye: the effect of calcium ointment through eyelid skin delivery. Br J Ophthalmol. 1999;83:767–770. doi:10.1136/bjo.83.7.767
   PubMed Web of Science ®Google Scholar
• Ubels JL, Edelhauser HF, Foley KM, et al. Current eye research. Curr Eye Res. 1985;4:1049–1057. doi:10.3109/02713688509003350
   PubMed Web of Science ®Google Scholar
• Ozgur O, Kaufman EJ. Ectropion. Treasure Island (FL); 2023.
   Google Scholar
• Panshak T, Ramyil AV, Maigida NB, et al. Conservative management of congenital unilateral eyelid ectropion in a 3-day-old neonate in Jos North-Central Nigeria. J West African Coll Surg. 2022;12:104–106. doi:10.4103/jwas.jwas_67_22
   PubMedGoogle Scholar
• Kato M, Kido K, Oda T. Ursodeoxycholic acid-containing agent for treating or preventing presbyopia. Japan: United States Patent; 2019.
   Google Scholar
• Kido K, Nagano T. Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage. Japan; 2018. p. 1–6.
   Google Scholar
• Aberg AKG, Johnson K. Ocular Formulations of Norketotifen. United States: United States Patent; 2015. p. 1–15.
   Google Scholar
• Fung SC, Yao Z. Use of complement inhibitors to treat ocular diseases. United States: United States Patent; 2014. p. 1–5.
   Google Scholar
• Rekik R. Folic acid – Ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions. Australia: Australian Patent Office; 2012. p. 1–34.
   Google Scholar
• Dana R, Chauhan S. Therapeutic Compositions for the Treatment of Dry Eye Disease. United States: United States Patent; 2011. p. 1–10.
   Google Scholar
• Aukunuru J, Saunier MB, Bizec J, et al. Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent. United States Patent; 2006. p. 1–10.
   Google Scholar
• Kasama T, Noto M, Oguro T, et al. Ophthalmic ointments for treating infective eye disease. Japan: United States Patent; 2005.
   Google Scholar
• Chen J, Liu Y. Pharmaceutical compositions and methods for treating immune-response associated diseases of the surface and the anterior segment of the eye. United States: United States; 2003. p. 1–8.
   Google Scholar
• Thomas PG. Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor. United States: United States Patent; 1998. p. 1–9.
   Google Scholar
• Djordjevic ND, Kofler B, Kramaric A, et al. Ophthalmic ointments for the treatment of glaucoma, comprising ergot alkaloids. Slovenia: European Patent Office; 1989.
   Google Scholar
• Hospital NTU. Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis. Taiwan; 2018.
   Google Scholar
• Bobby Korn. Efficacy of Loteprednol Ointment Following Eyelid Surgery. San Diego; 2019.
   Google Scholar
• Azura Ophthalmics. A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED). New South Wales, Australia; 2022.
   Google Scholar
• Qi H. Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction. Beijing, China; 2022.
   Google Scholar
• Siriraj Hospital. Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivits (VKC). Bangkok, Thailand; 2005.
   Google Scholar
• University of California. Village Integrated Eye Workers Trial (VIEW). Bharatpur, Nepal; 2023.
   Google Scholar
• Bausch & Lomb Incorporated. Atropine sulfate ointment [Internet]. 1990. Available from: https://www.webmd.com/drugs/2/drug-8614-5099/atropine-ophthalmic-eye/atropine-sulfate-ointment-ophthalmic/details
   Google Scholar
• FDC Ltd. Zoxan eye ointment [Internet]. Available from: https://www.1mg.com/drugs/zoxan-eye-ointment-565913
   Google Scholar
• Entod Pharmaceuticals Ltd. Omeflox BM eye ointment [Internet]. Available from: https://www.1mg.com/drugs/omeflox-bm-eye-ointment-250604
   Google Scholar
• Kumar A, Malviya R, Sharma P. Recent trends in ocular drug delivery: a short review recent trends in ocular drug delivery: a short review. Eur J Appl Sci. 2011;3:86–92.
   Google Scholar
• Spectra Vision Care. Remoxy eye ointment [Internet]. Available from: https://www.spectravisioncare.in/product/moxifloxacin-eye-ointment
   Google Scholar
• Pharmaceuticals K. Newflo eye ointment [Internet]. Available from: https://kaizenpharmaceuticals.in/product/newflo-ointment/
   Google Scholar
• Glaxo SmithKline Pharmaceuticals Ltd. Neosporin eye ointment [Internet]. Available from: https://india-pharma.gsk.com/media/6392/neosporin-ointment.pdf
   Google Scholar
• RGS Pharmaceuticals Private Limited. RG TOB [Internet]. Available from: https://www.indiamart.com/proddetail/tobramycin-eye-ointment-25857517012.html
   Google Scholar
• Biocon Biologics India Limited. TBIS 0.1% [Internet]. Available from: https://www.apollopharmacy.in/medicine/tbis-0-1-ointment-10gm
   Google Scholar
• Medicom Healthcare Ltd. Golden Eye ointment [Internet]. Available from: https://www.goldeneyecare.co.uk/assets/leaflets/Golden-Eye-Chloramphenicol-1-EO-PV5-TUB.pdf
   Google Scholar
• Syntho Pharma. Cortecycline eye ointment [Internet]. Available from: https://www.1mg.com/drugs/cortecycline-eye-ointment-146177
   Google Scholar
• Optho Pharma Pvt. Ltd. NACL 6 eye ointment [Internet]. Available from: https://www.1mg.com/drugs/nacl-6-eye-ointment-234949
   Google Scholar
• Sensomed. Sensomed Erythromycin [Internet]. Available from: https://www.mims.com/philippines/drug/info/sensomed%20erythromycin
   Google Scholar
• Micro Labs Ltd. Phytoral ointment [Internet]. Available from: https://www.1mg.com/drugs/phytoral-ointment-329419
   Google Scholar
• World Health Organization. Medical Product Alert N°2/2023: tetracycline hydrochloride ophthalmic ointment USP 1%. World Heal. Organ; 2023. p. 1–4.
   Google Scholar
• Kiran MD, Sheikh SN, Pawaskar LJ. Safety and efficacy of a combination of chloramphenicol, polymyxin-b and dexamethasone in ocular infection with inflammation. Int J Innov Res Med Sci. 2018;03:1612–1617.
   Google Scholar
• Mindel JS, Mishima S, Wilhelmus KR, et al. Therapeutic review tobramycin in ophthalmology. Surv Ophthalmol. 1987;32:111–122.
   PubMedGoogle Scholar
• Chauhan M, Kumar S, Biswas A, et al. A comprehensive review of the advancement in omic technologies in the field of drug discovery and development. Lett Drug Des Discov. 2024;21:1–13. doi:10.2174/0115701808287654240126112003
   Google Scholar